Izotropic Corporation’s (CSE: IZO) (OTCQB: IZOZF) Leverages AI with Next-Gen Breast CT Imaging System
Izotropic Corporation (OTCQB: IZOZF) announced placement in an editorial by NetworkNewsWire on October 24, 2025 highlighting AI-driven imaging firms targeting the breast cancer market.
The company is noted for its IzoView Breast CT Imaging System, a purpose-built 3D solution aimed at improving detection accuracy, especially in women with dense breast tissue. The release cites WHO and ACS data on global and U.S. breast cancer incidence to frame market demand.
Izotropic Corporation (OTCQB: IZOZF) ha annunciato una pubblicazione in un editoriale di NetworkNewsWire il 24 ottobre 2025, evidenziando aziende di imaging guidate dall'IA che mirano al mercato del cancro al seno.
L'azienda è nota per il IzoView Breast CT Imaging System, una soluzione 3D su misura finalizzata a migliorare l'accuratezza del rilevamento, in particolare nelle donne con tessuto mammario denso. Il comunicato cita dati dell'OMS e dell'ACS sull'incidenza globale e statunitense del cancro al seno per inquadrare la domanda di mercato.
Izotropic Corporation (OTCQB: IZOZF) anunció su colocación en un editorial de NetworkNewsWire el 24 de octubre de 2025, destacando empresas de imágenes impulsadas por IA que apuntan al mercado del cáncer de mama.
La empresa es conocida por su IzoView Breast CT Imaging System, una solución 3D diseñada para mejorar la precisión de detección, especialmente en mujeres con tejido mamario denso. El comunicado cita datos de la OMS y la ACS sobre la incidencia global y en EE. UU. del cáncer de mama para enmarcar la demanda del mercado.
Izotropic Corporation (OTCQB: IZOZF)는 2025년 10월 24일 NetworkNewsWire의 에디토리얼에서 배치 발표를 알리며 AI 기반 영상 기업들을 유방암 시장을 목표로 조명했습니다.
회사는 IzoView Breast CT Imaging System이라는 목적에 맞춘 3D 솔루션으로, 특히 밀집한 유방 조직을 가진 여성의 검출 정확도를 향상시키는 것을 목표로 합니다. 발표는 시장 수요를 설명하기 위해 세계보건기구(WHO)와 미국암학회(ACS)의 전 세계 및 미국의 유방암 발병 데이터를 인용합니다.
Izotropic Corporation (OTCQB: IZOZF) a annoncé son placement dans un éditorial de NetworkNewsWire le 24 octobre 2025, mettant en lumière des entreprises d'imagerie pilotées par l'IA ciblant le marché du cancer du sein.
La société est connue pour son IzoView Breast CT Imaging System, une solution 3D conçue pour améliorer la précision du dépistage, en particulier chez les femmes ayant un tissu mammaire dense. Le communiqué cite les données de l'OMS et de l'ACS sur l'incidence mondiale et américaine du cancer du sein afin de cadrer la demande du marché.
Izotropic Corporation (OTCQB: IZOZF) gab in einem Editorial von NetworkNewsWire am 24. Oktober 2025 bekannt, dass AI-gesteuerte Bildgebungsunternehmen, die den Brustkrebsmarkt ansprechen, hervorgehoben werden.
Das Unternehmen ist bekannt für sein IzoView Breast CT Imaging System, eine zweckgebundene 3D-Lösung, die darauf abzielt, die Detektionsgenauigkeit zu verbessern, insbesondere bei Frauen mit dichtem Brustgewebe. Die Veröffentlichung verweist auf Daten der WHO und der ACS zur globalen bzw. US-Inzidenz von Brustkrebs, um die Marktnachfrage zu rahmen.
Izotropic Corporation (OTCQB: IZOZF) أعلنت الإدراج في افتتاحية لـ NetworkNewsWire في 24 أكتوبر 2025، مع تسليط الضوء على شركات التصوير المدفوعة بالذكاء الاصطناعي التي تستهدف سوق سرطان الثدي.
وتُعرف الشركة بـ IzoView Breast CT Imaging System، وهي حل ثلاثي الأبعاد مخصص يهدف إلى تحسين دقة الكشف، خاصة لدى النساء ذوات أنسجة الثدي الكثيفة. وتستشهد الرسالة ببيانات منظمة الصحة العالمية وACS حول معدل الإصابة بسرطان الثدي على المستوى العالمي وفي الولايات المتحدة لإطار الطلب في السوق.
- None.
- None.
NEW YORK, Oct. 24, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community.
To view the full publication, “Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market,” please visit: https://nnw.fm/qBAbh
Artificial intelligence (AI) continues to transform healthcare innovation, with medical imaging emerging as one of its most promising frontiers. In breast cancer detection, where early identification often determines patient outcomes, AI-powered imaging technologies are pushing beyond the technical constraints of traditional mammography, tomosynthesis, and MRI. Globally, breast cancer remains the most frequently diagnosed cancer among women. The World Health Organization (WHO) reported that more than 2.3 million women were diagnosed, with approximately 670,000 losing their lives to the disease in 2022. In the United States, the American Cancer Society (ACS) estimates that 316,950 new invasive breast cancer cases will be identified this year alone.
This urgent demand for faster, more accurate diagnostic tools is driving a surge of innovation across the imaging sector. Within this fast-evolving field, Izotropic Corporation is distinguishing itself with the IzoView Breast CT Imaging System, a purpose-built 3D imaging solution engineered to enhance cancer detection accuracy, particularly in women with dense breast tissue.
About Izotropic Corporation
Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) is a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses and treatment of breast cancers
More information about Izotropic can be found on its website at IzoCorp.com
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at https://ibn.fm/IZOZF
About NetworkNewsWire
NetworkNewsWire (“NNW”) is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: https://www.NetworkNewsWire.com/Disclaimer
NetworkNewsWire
New York, NY
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is powered by IBN
FAQ
What did Izotropic (OTCQB: IZOZF) announce on October 24, 2025?
What is the IzoView Breast CT Imaging System mentioned in the October 24, 2025 release?
How does the October 24, 2025 announcement frame market need for Izotropic (IZOZF)?
Where was Izotropic featured on October 24, 2025 and how can investors view it?
Does the October 24, 2025 release claim regulatory approvals for IzoView?
Will the October 24, 2025 placement in NetworkNewsWire directly change Izotropic's financial guidance?
